Jump to content

Biotechnology industry in Italy: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 8: Line 8:
* The first [[Ebola vaccine]] in the world was developed in the IRBM Science Park laboratories, [[Pomezia]], [[Rome]], [[Italy]].<ref>{{cita news|titolo=Ebola, con il vaccino sviluppato in italia si ottiene l'immunità per 10 mesi|url=http://www.repubblica.it/salute/medicina/2014/09/07/news/ebola_vaccino_italia-95202298/|accesso=26 novembre 2015|data=7 settembre 2014|sito=La Repubblica}}</ref>
* The first [[Ebola vaccine]] in the world was developed in the IRBM Science Park laboratories, [[Pomezia]], [[Rome]], [[Italy]].<ref>{{cita news|titolo=Ebola, con il vaccino sviluppato in italia si ottiene l'immunità per 10 mesi|url=http://www.repubblica.it/salute/medicina/2014/09/07/news/ebola_vaccino_italia-95202298/|accesso=26 novembre 2015|data=7 settembre 2014|sito=La Repubblica}}</ref>
In the laboratories of the IRBM Science Park a team of Italian and American researchers has developed the Chad3Ebola-Zaire anti-ebola vaccine, a monovalent adenovirus capable of neutralizing the «Zaire» strain of the virus, conceived and produced by OKAIROS, a biotech company founded by Prof. Riccardo Cortese, with whom IRBM set up the Advent equal joint venture.
In the laboratories of the IRBM Science Park a team of Italian and American researchers has developed the Chad3Ebola-Zaire anti-ebola vaccine, a monovalent adenovirus capable of neutralizing the «Zaire» strain of the virus, conceived and produced by OKAIROS, a biotech company founded by Prof. Riccardo Cortese, with whom IRBM set up the Advent equal joint venture.
* A [[COVID-19 vaccine]] was developed in the IRBM Science Park laboratories, [[Pomezia]], [[Rome]], [[Italy]] in cooperation with [[Jenner Institute]] [[Oxford University]].<ref>{{cite web |title=Vaccino Oxford-Pomezia, a settembre 400 milioni di dosi: accordo con multinazionale Astrazeneca. Fondi anche dagli Usa |url=https://www.ilmessaggero.it/salute/ricerca/vaccino_quando_arriva_oxford_pomezia_usa_dosi_ultime_notizie_news-5241097.html |website=ilmessaggero.it |publisher=ilmessaggero.it |accessdate=3 August 2020}}</ref><ref>{{cite web| url=https://www.irbm.com/news/the-jenner-institute-signs-an-agreement-with-advent-to-develop-a-novel-coronavirus-vaccine/ | title=The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine | publisher=IRBM}}</ref>
* A [[COVID-19 vaccine]] was developed in the IRBM Science Park laboratories, [[Pomezia]], [[Rome]], [[Italy]] in cooperation with [[Jenner Institute]] [[Oxford University]].<ref>{{cite web |title=Vaccino Oxford-Pomezia, a settembre 400 milioni di dosi: accordo con multinazionale Astrazeneca. Fondi anche dagli Usa |url=https://www.ilmessaggero.it/salute/ricerca/vaccino_quando_arriva_oxford_pomezia_usa_dosi_ultime_notizie_news-5241097.html |website=ilmessaggero.it |publisher=ilmessaggero.it |accessdate=3 August 2020}}</ref><ref>{{cite web| url=https://www.irbm.com/news/the-jenner-institute-signs-an-agreement-with-advent-to-develop-a-novel-coronavirus-vaccine/ | title=The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine | publisher=IRBM}}</ref><ref>{{cite news |title=Vaccino Covid-19, sprint di azienda italiana: a fine aprile i test sull’uomo |url=https://www.ilsole24ore.com/art/vaccino-covid-19-sprint-dell-italiana-advent-via-test-sull-uomo-ADRUczJ |accessdate=3 August 2020 |agency=ilsole24ore.com |publisher=ilsole24ore.com |date=13 April 2020}}</ref>


==Agricultural biotechnology==
==Agricultural biotechnology==

Revision as of 20:58, 3 August 2020

Biotechnology industry in Italy is a highly innovative and fast growing sector dedicated to research. At the end of 2019, there are 696 biotech companies active in Italy.[1]

Industry

The turnover exceeds 12 billion euros, the number of employees exceeds 13,000 units. Between 2017 and 2019, over 50 new innovative start-ups active in biotechnology were registered.[2]

Healthcare

Vaccine

In the laboratories of the IRBM Science Park a team of Italian and American researchers has developed the Chad3Ebola-Zaire anti-ebola vaccine, a monovalent adenovirus capable of neutralizing the «Zaire» strain of the virus, conceived and produced by OKAIROS, a biotech company founded by Prof. Riccardo Cortese, with whom IRBM set up the Advent equal joint venture.

Agricultural biotechnology

Research

The research intensity of the biotech sector is significantly higher than that found for the Italian industry as a whole.[7]

Organizations

Ministries

Agencies

Science parks and incubators

  • Istituto di Ricerca di Biologia Molecolare P. Angeletti SpA (IRBM)
  • IRBM Science Park

See also

References

  1. ^ "La fotografia delle imprese di biotecnologie in Italia". assobiotec.federchimica.it. assobiotec.federchimica.it. Retrieved 3 August 2020.
  2. ^ "La fotografia delle imprese di biotecnologie in Italia". assobiotec.federchimica.it. assobiotec.federchimica.it. Retrieved 3 August 2020.
  3. ^ "Ebola, con il vaccino sviluppato in italia si ottiene l'immunità per 10 mesi". La Repubblica. 7 September 2014. Retrieved 26 November 2015.
  4. ^ "Vaccino Oxford-Pomezia, a settembre 400 milioni di dosi: accordo con multinazionale Astrazeneca. Fondi anche dagli Usa". ilmessaggero.it. ilmessaggero.it. Retrieved 3 August 2020.
  5. ^ "The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine". IRBM.
  6. ^ "Vaccino Covid-19, sprint di azienda italiana: a fine aprile i test sull'uomo". ilsole24ore.com. ilsole24ore.com. 13 April 2020. Retrieved 3 August 2020.
  7. ^ "La fotografia delle imprese di biotecnologie in Italia". assobiotec.federchimica.it. assobiotec.federchimica.it. Retrieved 3 August 2020.

This article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Biotechnology_industry_in_Italy&oldid=971041921"